CytoSorbents Corporation (CTSO)

[Bsbs12]

Jan 28, 2020, 07:01 ET

MONMOUTH JUNCTION, N.J. , Jan. 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a critical care immunotherapy leader with more than 80,000 global treatments of its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights the recent publication in The Lancet entitled, " Clinical features of patients infected with 2019 novel coronavirus in Wuhan , China ." The article notes the correlation of high levels of circulating inflammatory cytokines, or "cytokine storm," with severity of illness in patients infected with the Wuhan coronavirus (2019-nCoV). These data provide the rationale to potentially use CytoSorb, the first specifically-approved extracorporeal cytokine adsorber in the European Union, in this setting. CytoSorb is distributed in 58 countries worldwide, and is available in Hong Kong , Vietnam , Malaysia , France , and Australia where patients infected with the virus have been reported.